TERAPI BEDAH PEMANJANGAN TUNGKAI VS TERAPI OBAT HORMONAL VOSORITIDE PADA PENDERITA AKONDROPLASIA : SYSTEMATIC REVIEW
Introduction: Achondroplasia is a bone growth disorder caused by mutations in the fibroblast growth factor-receptor-3 (FGFR-3) gene that causes the body to be short and disproportionate. This condition can be modified bylimb lengthening therapyother hand, various studies to date have shown that the...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
2022-01-12.
|
| Subjects: | |
| Online Access: | Link Metadata |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | repoupnvj_16286 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Ameliana, . |e author |
| 245 | 0 | 0 | |a TERAPI BEDAH PEMANJANGAN TUNGKAI VS TERAPI OBAT HORMONAL VOSORITIDE PADA PENDERITA AKONDROPLASIA : SYSTEMATIC REVIEW |
| 260 | |c 2022-01-12. | ||
| 500 | |a http://repository.upnvj.ac.id/16286/1/ABSTRAK.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/2/AWAL.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/3/BAB%20I.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/4/BAB%20II.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/5/BAB%20III%20%282%29.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/7/BAB%20IV.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/8/BAB%20V.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/9/DAFTAR%20PUSTAKA.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/10/RIWAYAT%20HIDUP.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/12/LAMPIRAN.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/13/HASIL%20PLAGIARISME.pdf | ||
| 500 | |a http://repository.upnvj.ac.id/16286/14/ARTIKEL%20KI.pdf | ||
| 520 | |a Introduction: Achondroplasia is a bone growth disorder caused by mutations in the fibroblast growth factor-receptor-3 (FGFR-3) gene that causes the body to be short and disproportionate. This condition can be modified bylimb lengthening therapyother hand, various studies to date have shown that the C-natriuretic peptide (vosoritide) analogue is a promising therapy to increase the height of patients with achondroplasia. This review aims to determine the effectiveness and safety of both therapies. Methods: The literature search process was carried out using the SCOPUS, Pubmed, Science direct, Google Scholar, DOAJ databases. Results: In systematic review , based on 5 research literatures that have been selected using the PRISMA-P method, it shows that limb lengthening surgical therapy increases height with an average height gain that is almost as planned. In 4 literatures with vosoritide increase in growth rate was obtained up to 5.52 cm/year. The complication rate after limb lengthening surgery was higher than vosoritide with no complications found in the literature. Conclusion: Surgical treatment of limb lengthening increases the height of patients with achondroplasia more quickly but the complications caused are not lower than that of the hormonal drug vosoritide. | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 546 | |a id | ||
| 690 | |a RD Surgery | ||
| 690 | |a RM Therapeutics. Pharmacology | ||
| 655 | 7 | |a Thesis |2 local | |
| 655 | 7 | |a NonPeerReviewed |2 local | |
| 787 | 0 | |n http://repository.upnvj.ac.id/16286/ | |
| 787 | 0 | |n http://repository.upnvj.ac.id | |
| 856 | 4 | 1 | |u http://repository.upnvj.ac.id/16286/ |z Link Metadata |